<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>Annals of Internal Medicine: Smoking Topic Collection</title>
    <link>http://annals.org/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Tue, 07 May 2013 00:00:00 GMT</pubDate>
    <lastBuildDate>Mon, 06 May 2013 22:53:59 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@annals.org</managingEditor>
    <webMaster>webmaster@annals.org</webMaster>
    <item>
      <title>Action to Stop Smoking in Suspected Tuberculosis (ASSIST) in Pakistan A Cluster Randomized, Controlled Trial </title>
      <link>http://annals.org/article.aspx?articleID=1684852</link>
      <pubDate>Tue, 07 May 2013 00:00:00 GMT</pubDate>
      <author>Siddiqi K, Khan A, Ahmad M, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Background:&lt;/div&gt;Tobacco use is responsible for a large proportion of the total disease burden from tuberculosis. Pakistan is one of the 10 high-burden countries for both tuberculosis and tobacco use.&lt;div class="boxTitle"&gt;Objective:&lt;/div&gt;To assess the effectiveness of a behavioral support intervention and bupropion in achieving 6-month continuous abstinence in adult smokers with suspected pulmonary tuberculosis.&lt;div class="boxTitle"&gt;Design:&lt;/div&gt;Cluster randomized, controlled trial. (Current Controlled Trials: ISRCTN08829879)&lt;div class="boxTitle"&gt;Setting:&lt;/div&gt;Health centers in the Jhang and Sargodha districts in Pakistan.&lt;div class="boxTitle"&gt;Patients:&lt;/div&gt;1955 adult smokers with suspected tuberculosis.&lt;div class="boxTitle"&gt;Intervention:&lt;/div&gt;Health centers were randomly assigned to provide 2 brief behavioral support sessions (BSS), BSS plus 7 weeks of bupropion therapy (BSS+), or usual care.&lt;div class="boxTitle"&gt;Measurements:&lt;/div&gt;The primary end point was continuous abstinence at 6 months after the quit date and was determined by carbon monoxide levels in patients. Secondary end points were point abstinence at 1 and 6 months.&lt;div class="boxTitle"&gt;Results:&lt;/div&gt;Both treatments led to statistically significant relative risks (RRs) for abstinence compared with usual care (RR for BSS+, 8.2 [95% CI, 3.7 to 18.2]; RR for BSS, 7.4 [CI, 3.4 to 16.4]). Equivalence between the treatments could not be established. In the BSS+ group, 275 of 606 patients (45.4% [CI, 41.4% to 49.4%]) achieved continuous abstinence compared with 254 of 620 (41.0% [CI, 37.1% to 45.0%]) in the BSS group and 52 of 615 (8.5% [CI, 6.4% to 10.9%]) in the usual care group. There was substantial heterogeneity of program effects across clusters.&lt;div class="boxTitle"&gt;Limitations:&lt;/div&gt;Imbalances in the urban and rural proportions and smoking habits among treatment groups, and inability to confirm adherence to bupropion treatment and validate longer-term abstinence or the effect of smoking cessation on tuberculosis outcomes.&lt;div class="boxTitle"&gt;Conclusion:&lt;/div&gt;Behavioral support alone or in combination with bupropion is effective in promoting cessation in smokers with suspected tuberculosis.&lt;div class="boxTitle"&gt;Primary Funding Source:&lt;/div&gt;International Development Research Centre.&lt;/span&gt;</description>
      <guid>http://annals.org/article.aspx?articleID=1684852</guid>
    </item>
  </channel>
</rss>